Health Care · FY2025 10‑K ↗ LLY · NYSE
ELI LILLY & Co
1876 2025
1876 Company Founded
1898 Leadership Transition
1905 Major Milestone
1919 Research Expansion
1971 Diversification
2003 Major Drug Launch
2004 Success and Controversy
2005 Innovation Success
2007 Strategic Acquisition
2008 Legal and Regulatory Pressure
2021 Growth Acceleration Begins
2023 Explosive Growth
2024 Breakout Year
2025 Record Revenue
Wikipedia history · XBRL financial data

Eli Lilly makes medicines that patients take every day, often for the rest of their lives. The company earns money by selling those medicines to pharmacies, hospitals, and health plans in about 90 countries. Its biggest products right now are Mounjaro and Zepbound, two medicines that treat type 2 diabetes and obesity. Because patients need refills continuously, revenue does not depend on one-time purchases. That makes the model look more like a utility than a store. The diagram below traces where the money goes.

How Eli Lilly Makes Money
flowchart LR A["R&D: Drug Discovery and Development"] --> B["Regulatory Approval FDA, EMA, others"] B --> C["Product Launch 61.0B product revenue"] C --> D["Sales to Healthcare Distributors, Pharmacies"] D --> E["Patient Access via LillyDirect and Distribution"] E --> F["Product Revenue 65.2B total, 83% margin"] F --> G["Operating Cash Flow 16.8B annually"] G --> H["Patent Protection Compound patents Data protection"] H --> I["Market Exclusivity Blocks generic competition"] I --> C F --> A G --> A D --> H

Five years of numbers tell a story of rapid acceleration. Revenue held fairly flat from 2021 to 2022, then jumped as newer medicines took hold. By 2025 the company was reporting $65.2 billion in annual revenue, more than double what it earned in 2021. That is not slow, steady growth. That is a step change.

Annual Revenue 2021 to 2025 (USD billions)
2021
$28.3B
2022
$28.5B
2023
$34.1B
2024
$45.0B
2025
$65.2B
Revenue was essentially flat in 2021 to 2022, then accelerated sharply as Mounjaro and Zepbound volumes grew.

Gross margin tells a similarly strong story. Every dollar of revenue keeps more and more after paying for manufacturing. Gross margin rose from 74 percent in 2021 to 83 percent in 2025. That improvement came from a better product mix and lower production costs per unit. It means the business is not just getting bigger. It is getting more efficient as it grows.

83%
Gross margin in 2025, up from 74% in 2021

Operating cash flow tells a more complicated story. It rose from $7.4 billion in 2021 to $16.8 billion in 2025, which sounds great. But free cash flow, which is what remains after spending on factories and equipment, stayed much lower. In 2023 free cash flow nearly disappeared, dropping to $0.8 billion. Capital spending on new manufacturing facilities has been enormous. The company spent $7.8 billion on capital expenditures in 2025 alone, compared with $5.1 billion in 2024. The business is generating cash faster than ever, but it is also pouring that cash back into building more capacity.

$16.8B
Operating cash flow 2025
$3.8B
Free cash flow 2025
The $13 billion gap between operating cash and free cash flow reflects heavy factory investment. In 2023 free cash flow was just $0.8 billion.

Net debt has climbed steadily alongside that spending. It stood at $13.1 billion in 2021 and reached $35.2 billion by 2025. The company is borrowing to build. That is a deliberate bet that future demand will fill the factories being built today.

What is patent protection?
When a drug company creates a new medicine, it gets a patent that stops other companies from copying it for a set number of years. Once that patent expires, cheaper generic versions can enter the market, and the original drug often loses most of its sales very quickly. Protecting the patent window is one of the most important jobs in the pharmaceutical business.

The risk picture is unusually concentrated. Six products generated 82 percent of total revenues in 2025. Mounjaro and Zepbound alone accounted for 56 percent of total revenues that year. That means two medicines are carrying more than half the entire business. If anything goes wrong with either one, the financial impact would be immediate and large. The Trulicity patent, which covers another major diabetes medicine, is set to expire in the U.S. in 2027. When patents expire, generic competitors can enter quickly and prices tend to fall fast.

56%
Share of 2025 total revenue from just Mounjaro and Zepbound

The U.S. government has added a new layer of pressure. A law called the Inflation Reduction Act lets Medicare set prices directly for certain medicines. Jardiance was selected first, with government-set prices starting in 2026. Trulicity and Verzenio were selected next, with prices set to take effect in 2028. The company has said it expects more of its products to be selected in future years. These price controls do not eliminate revenue, but they reduce how much the company earns per prescription on some of its most important medicines.

What is Medicare price negotiation?
Medicare is the U.S. government health program for people 65 and older. Under the Inflation Reduction Act, the government can now directly negotiate lower prices on certain widely used medicines. Once a price is set, drug companies must accept it for Medicare sales or face steep penalties. This is a significant change from the previous system where companies set their own prices.

The supply chain carries its own risks. The company depends on China-based suppliers for critical ingredients. Geopolitical tensions, tariffs, or disruptions at those suppliers could cause shortages or delays. Pharmaceuticals are currently exempt from some tariffs, but that exemption could change. Building new manufacturing inside the U.S. and elsewhere takes years and billions of dollars, and there is no guarantee the new capacity will be finished on time or will meet actual demand.

2023
milestone
The Incretin Inflection Point
Mounjaro launched for diabetes and Zepbound followed for obesity. These two medicines, both built on the same active ingredient tirzepatide, transformed the company's revenue trajectory almost overnight. By 2025 they together generated more revenue than the entire company did in 2021. The manufacturing expansion now underway is a direct response to that demand.

An additional competitive threat comes from compounded versions of incretin medicines. Pharmacies that mix their own drug preparations have been producing versions of tirzepatide, the active ingredient in Mounjaro and Zepbound. The company has said these practices create patient safety risks and market confusion. The FDA confirmed in late 2024 that a shortage period had ended and that mass compounding should stop, but the company has said it cannot guarantee adequate regulation or compliance.

Orforglipron, a pill-based obesity medicine under regulatory review in 2025, could eventually offer a less expensive and easier-to-manufacture alternative to injectable incretins. The company received a priority review voucher from the FDA for this product, which could speed up its approval timeline.
$7.8B
Capital expenditure in 2025, nearly double the $5.1B spent in 2024, funding new manufacturing capacity
The Bet
Mounjaro and Zepbound must keep growing fast enough, and for long enough, to pay off the tens of billions of dollars being borrowed and spent on new factories before patent cliffs and government price controls shrink the revenue those factories were built to serve. The company is also betting that its pipeline, including orforglipron and other incretin medicines in late-stage trials, will arrive in time to replace revenue that Trulicity and other ageing products will lose to generics. If the pipeline is late, if demand for tirzepatide plateaus sooner than expected, or if government price controls extend more aggressively across the portfolio, then the debt taken on to build capacity becomes a burden rather than a foundation.
Open question
Eli Lilly has built one of the fastest-growing revenue bases in the pharmaceutical industry, almost entirely on the strength of two medicines that treat diabetes and obesity. The factories, the debt, and the pipeline spending all assume that growth continues. But the government is already setting prices on key products, patents are expiring, and two medicines account for more than half of all revenue. Can the pipeline deliver enough new blockbusters, fast enough, to sustain a business that has grown so rapidly it now needs $35 billion in net debt and billions more in annual capital spending just to keep up with itself?
Compiled · 10-K · FY2025
Total Revenue (5-year)
2021
$28B
2022
$29B
2023
$34B
2024
$45B
2025
$65B
Revenue grew from $28B in 2021 to $65B in 2025, a 130% increase over 5 years.
XBRL · Total revenue · Segment breakdown not reported separately
Gross Margin Trend (5-year)
2021 2025
Gross margin moved from 74.2% (2021) to 83.0% (2025).
Operating Cash Flow (5-year)
2021
$7.4B
2022
$7.6B
2023
$4.2B
2024
$8.8B
2025
$17B
Cash Conversion
0.81×
At 0.81×, the company is converting less than 85 cents of operating cash per dollar of net income, worth watching over time.
XBRL · 10-K Financial Statements · FY2025
FY2025
$35B
↑ 16% year over year
FY2024
$30B
Net debt rose 16% year over year, the company added more debt than it repaid.
XBRL · Balance Sheet · 10-K · FY2025
David A. Ricks
Chief Executive Officer
$37M
Lucas Montarce
Executive Vice President and Chief Financial Officer
Compensation data not available
Jake Van Naarden
Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development
$8M
Chair, President, and Chief Executive Officer
Named Executive Officer
$2M, mostly cash
Daniel M. Skovronsky, M.D., Ph.D.
Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Labs
Compensation data not available
DEF 14A · Proxy Statement
Jun 10, 2026
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
$2.88M
May 6, 2026
LILLY ENDOWMENT INC
$13.55M
May 6, 2026
LILLY ENDOWMENT INC
$2.20M
Jan 7, 2026
LILLY ENDOWMENT INC
$0.97M
Jan 7, 2026
LILLY ENDOWMENT INC
$8.35M
Jan 7, 2026
LILLY ENDOWMENT INC
$1.16M
Jan 7, 2026
LILLY ENDOWMENT INC
$1.01M
Jan 7, 2026
LILLY ENDOWMENT INC
$3.90M
Jan 7, 2026
LILLY ENDOWMENT INC
$1.34M
Jan 7, 2026
LILLY ENDOWMENT INC
$1.17M
9 purchases and 495 sales by insiders over the past two years.
Form 4 · SEC filings · Last 24 months
Vanguard Group
9.1%
BlackRock
7.3%
PNC FINANCIAL SERVICES GROUP, INC.
5.7%
State Street
4.0%
Fidelity (FMR LLC)
2.9%
Capital Research Global
2.8%
Geode Capital Management
2.2%
Morgan Stanley
1.7%
Vanguard Group is the largest institutional holder with 9.1% of shares outstanding.
13F filings
Pipeline Risk
The company must continuously develop new successful medicines to replace revenue lost when existing products lose patent protection or face competition. If the company fails to replenish its product pipeline in time, it will materially harm the business, cash flows, and financial position.
Revenue Concentration
Six products generated 82 percent of total revenues in 2025, with Mounjaro and Zepbound alone accounting for 56 percent. Loss of patent protection, safety concerns, supply disruptions, or competitive pressure on any of these major products could cause significant and sudden revenue declines.
U.S. Government Price Controls
The U.S. government has selected three of the company's major medicines for price-setting in Medicare at significant discounts (Jardiance starting 2026, Trulicity and Verzenio starting 2028), and the company expects more products will be selected. This accelerates revenue erosion across the product portfolio.
Patent Expiration
Trulicity will lose significant patent protection in the next few years. Loss of patent protection typically causes rapid and severe revenue declines, especially in the U.S. where generic competitors quickly enter the market.
Supply Chain Disruption
The company depends heavily on China-based suppliers for critical ingredients and materials. Geopolitical tensions, tariffs, or supplier failures could cause product shortages or manufacturing delays. The company is expanding manufacturing capacity at significant cost, but cannot guarantee it will be completed or meet future demand.
10-K Item 1A · Risk Factors
Cash vs earnings
AR growth
Inventory
Share dilution
Debt trend
·
One-time charges
Goodwill
·
Customer conc.
Cash collected is consistently below reported profits — worth watching.
Unsold products are piling up faster than sales are growing.
10-K · XBRL · Computed signals